Article Text

Download PDFPDF
Predictors of risk of relapse in classic Hodgkin lymphoma
  1. Jonathan R Fromm1,
  2. Claire Tang2,
  3. Kikkeri N Naresh3
  1. 1 Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA
  2. 2 University of Washington, Seattle, Washington, USA
  3. 3 Pathology / Cancer Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
  1. Correspondence to Dr Jonathan R Fromm, Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98115, USA; jfromm{at}u.washington.edu

Abstract

Using multiparametric flow cytometric analysis, in a cohort of 62 patients with classic Hodgkin lymphoma having a median follow-up period of 69.5 months, we found—patients who experienced primary resistance or disease relapse (DR) had lower percentage of rosetted Hodgkin Reed-Sternberg cells (HRS-cells) as compared with patients who achieved sustained complete remission (SCR) (p=0.022); patients >35 years of age had higher percentage of HRS-cells (p=0.017) and lower percentage of B cells (p=0.017) and the nodular sclerosis subtype had higher percentage of B-cells (p=0.046) and activated B-cells (p=0.03). The proportion of SCR and DR subsets did not differ by histological subtypes, disease stage or age groups.

  • FLOW CYTOMETRY
  • Hodgkin Disease
  • LYMPHOMA

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Handling editor Runjan Chetty.

  • Contributors JRF conceived of the project. JRF and KNN designed experiments. CT collected data. CT, JRF and KNN analysed the data. KNN wrote the first version of the manuscript. CT, JRF and KNN contributed to critical revision of the final manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.